Shire Files 8K - Changes Executive Management

Shire PLC (SHPG) filed a Form 8K - Changes in Company Executive Management - with the U.S Securities and Exchange Commission on November 19, 2014.

As Shire plc ("Shire") previously announced on Form 8-K filed October 20, 2014, James Bowling will be stepping down as interim Chief Financial Officer ("CFO") of Shire. On November 19, 2014, Shire announced that Jeff Poulton (47), Shire's Senior Vice President and Head of Investor Relations, will succeed Mr. Bowling as interim CFO with effect from January 1, 2015.

Mr. Poulton joined Shire in 2003 and in addition to his current role, has served in a number of positions including, in the past five years, as Senior Vice President and Head of Shire's Rare Disease Business Unit, Senior Vice President and General Manager for Americas and Asia Pacific Commercial Operations for Shire's Human Genetic Therapy Division, and Senior Vice President Finance for Shire's Human Genetic Therapy Division. Mr. Poulton is expected to enter into a new employment agreement governing the terms of his appointment as interim CFO.

Shire has issued the press release attached as Exhibit 99.1 hereto which is incorporated by reference herein.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010314008291/dp51347_8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010314008291/0000950103-14-008291-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires